Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Further Analysis Confirms Usefulness of SGN-36: Takeda
June 27, 2011
- Korosho to Invite Requests for Development of Unapproved Drugs/Applications in August
June 27, 2011
- Council Approves Basic Policy for Promotion of Medical Innovation
June 27, 2011
- Roche Confirms Efficacy of Actemra Monotherapy
June 27, 2011
- GenomIdea Ties Up with TSD Japan for Licensing HVJ-E
June 27, 2011
- Korosho to Create ICH GCP-Compliant “Clinical Research Core Hospitals”
June 27, 2011
- Miraka HD: Sales Up 11.2% with Addition of New Subsidiaries
June 27, 2011
- Bayer to Strengthen Its PV Division
June 20, 2011
- FDA Approves pNET as Additional Indication for Sutent: Pfizer
June 20, 2011
- Axitinib Increases PFS Compared to Sorafenib in Previously Treated RCC Patients: ASCO
June 20, 2011
- Bayer to Accumulate Medicoeconomic Evidence
June 20, 2011
- MediBIC: Glufosfamide Granted Orphan Drug Status in Europe
June 20, 2011
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…